Table 2 The regulatory role of LncRNAs in modulation of ferroptosis in HCC
From: Regulating ferroptosis by non-coding RNAs in hepatocellular carcinoma
miRNA | Expression/function | Targets | Effects on tumour | Refs. |
|---|---|---|---|---|
LncRNA DUXAP8 | ↑/Oncogene | SLC7A11 | Silencing LncRNA DUXAP8 boosts sorafenib-induced ferroptosis via de-palmitoylation of SLC7A11 | [127] |
LncRNA CASC11 | ↑/Oncogene | SLC7A11 | CASC11 inhibits sorafenib-induced ferroptosis via stabilizing SLC7A11 | [128] |
LncRNA SLC7A11-AS1 | ↑/Oncogene | SLC7A11 | SLC7A11-AS1 promots HCC cell growth and resistance to erastin-induced ferroptosis through stabilizing SLC7A11 mRNA | [129] |
LncRNA HEPFAL | ↓/Tumor suppressor | SLC7A11 | LncRNA HEPFAL accelerates ferroptosis by promoting the ubiquitination and degradation of SLC7A11 protein | [130] |
LncRNA NRAV | ↑/Oncogene | miR-375-3P/SLC7A11 | LncRNA NRAV promotes HCC tumorigenesis and inhibits ferroptosis through upregulating SLC7A11 via sponging miR-375-3P and attenuates its the inhibitory effect on SLC7A11 | [131] |
LncPVT1 | ↑/Oncogene | GPX4 | Overexpression of lncPVT1 and GPX4 impeded ketamine-induced ferroptosis | [132] |
LINC01134 | ↑/Oncogene | GPX4 | LINC01134 decreased oxaliplatin sensitivity by inhibiting ferroptosis through upregulating GPX4 | [133] |
LncRNA HCG18 | ↑/Oncogene | GPX4 | Silencing HCG18 inhibits sorafenib resistance through promoting ferroptosis via inhibiting GPX4 by binding to miR-450b-5p | [134] |
LncRNA PVT1 | -/Oncogene | miR-195-5p/PLAG1/GPX4 | LncRNA acts as a sponge for miR-195-5p to upregulate expression of PLAG1, which enhances the expression of GPX4, resulting in the inhibition of the ferroptosis signaling pathway | [135] |
LncFAL | ↑/Oncogene | FSP1 | HDLBP-mediated lncFAL stabilization promotes ferroptosis resistance by diminishing Trim69-dependent FSP1 degradation | [136] |
LncRNA URB1-AS1 | ↑/Oncogene | Ferritin | HIF-1α-mediated increased URB1-AS1 attenuates sorafenib-triggered ferroptosis by inducing ferritin phase separation and decreasing the cellular free iron content | [137] |
LncRNA SNHG1 | ↑/Oncogene | miR-199a | SNHG1 inhibits ferroptosis through upregulating FANCD2 and G6PD by sponging miR-199a | [138] |
LncRNA GABPB1-AS1 | ↑/Tumor suppressor | PRDX5 | LncRNA GABPB1-AS1 forms RNA duplexes with GABPB1 mRNA to inhibit GABPB1 translation, downregulate expression of PRDX5, which ultimately leads to ferroptosis | [139] |
LncRNA NEAT1 | ↓/Tumor suppressor | MIOX | NEAT1 promotes erastin and RSL3-induced ferroptosis by upregulating MIOX in HCC cells | [140] |
LncRNA HULC | ↑/Oncogene | miR-3200-5p/ATF4 | Decreased lncRNA HULC triggers ferroptosis via inhibiting miR-3200-5p/ATF4 Axis | [141] |
LncRNA EPS15-AS1 | ↓/Tumor suppressor | EPS15/AKR1B1 | EPS15-AS1 inhibits HCC cell activity and induces ferroptosis by decreasing EPS15 expression and thus downregulating AKR1B1 expression | [142] |